Charterhouse Capital Partners announces partial sale of Funecap, continues to support next phase of growth

Charterhouse Capital Partners LLP has announced the partial realisation of its investment in Funecap Groupe, a leading funeral services and crematoria provider in France, through the sale of a stake to Latour Capital.
Charterhouse Capital Partners announces partial sale of Funecap, continues to support next phase of growth
Charterhouse Capital Partners LLP (“Charterhouse”), one of the longest established private equity firms operating in Europe, announces today that it has agreed a partial realisation of its investment in Funecap Groupe (“Funecap” or “the Company”), the major funeral services and crematoria provider in France, in selling a stake to Latour Capital.

Founded in 2010 by Xavier Thoumieux and Thierry Gisserot and headquartered in Paris, Funecap is the second largest funeral provider in France. The Company operates across two broad funeral service categories: burial and cremation services, which cover all aspects of funeral organisation from logistics and service provision to administration and grave maintenance; and, management of crematoria on behalf of French local public authorities with 46 sites under management. Funecap has a nationwide presence through a direct network of approximately 450 operated agencies, 200 funeral homes and 46 crematoria. In addition, the business has 200 agencies, which operate under the company’s franchise network.

Since its investment in the business in July 2018, Charterhouse has supported the business in impressive growth driven by: organic initiatives, expanding the Company’s market share and increasing its service offering in its core markets; a ramp up of the crematoria business, with numerous new key concessions won; and, M&A, completing over 50 add-on acquisitions since its initial investment. The French funeral services market remains highly fragmented and presents a significant buy-and-build opportunity.

Charterhouse wishes to congratulate Funecap’s founders and management team, and looks forward to the continuation of their partnership as Funecap enters its next phase of growth. Charterhouse will retain an interest in the business and participate in future value creation alongside management and Latour Capital.
LikeDiscussion
Share

Discussion

You are commenting on Charterhouse Capital Partners announces partial sale of Funecap, continues to support next phase of growth

You must be logged in to add a comment

There are no comments

Be the first to add to the discussion

Charterhouse Capital Partners LLP
Charterhouse Capital Partners LLP
London, United Kingdom
Charterhouse is one of the longest established private equity firms operating in Europe. The firm connects expertise and capital, partnering with ambitious founders and management teams to drive transformational change. Charterhouse has a selective, conviction-led approach to investing in high-quality mid-market European companies across the Services, Healthcare, Specialised Industrials and Consumer sectors. It targets transactions with an enterprise value of between €200m and €1.5bn. Charterhouse’s international team works in an integrated and flexible manner, allowing the firm to combine the skills, knowledge and experience of its entire team to help build successful businesses over the long term. The firm has completed more than 150 acquisitions over 35 years of activity in the European buyout market.
buyoutprivate equity

Related news

Charterhouse Capital Partners announces investment in PHASTAR

Charterhouse Capital Partners announces investment in PHASTAR

Charterhouse Capital Partners LLP ("Charterhouse"), a leading private equity firm, has announced its investment in PHASTAR, a specialist provider of biostatistics and data science services for clinical trials. This partnership will see Charterhouse working alongside PHASTAR's founder and CEO, Kevin Kane, who will retain a significant shareholding and continue leading the company with its existing management team.

Charterhouse Capital Partners LLP
Charterhouse Capital Partners enters into exclusive negotiations for the sale of Cooper to CVC Capital Partners Fund VII and reinvestment in its next stage of growth

Charterhouse Capital Partners enters into exclusive negotiations for the sale of Cooper to CVC Capital Partners Fund VII and reinvestment in its next stage of growth

Charterhouse Capital Partners LLP has entered into exclusive negotiations for the sale of a majority stake in Cooper Consumer Health, a leading European independent over-the-counter (OTC) drug manufacturer and distributor, to CVC Fund VII. The transaction is subject to approval from relevant regulatory authorities and consultation with workers' councils.

Charterhouse Capital Partners LLP